InterGenetics Incorporated Release: First Genetic-Based Breast Cancer Risk Test Enters International Market

OKLAHOMA CITY--(BUSINESS WIRE)--InterGenetics, a predictive medicine company, focused on molecular diagnostics and targeted therapy for cancer, announced the international release of the first genetic-based, breast cancer risk test that incorporates both personal history and gene-based information to determine a woman’s future breast cancer risk. Opaldia, a genetic health service provider with a network of clinics, will release OncoVue® in the United Kingdom and Ireland under an exclusive agreement.